OncoMatch/Clinical Trials/NCT05730816
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Is NCT05730816 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Magnesium sulfate and Normal Saline for mesothelioma.
Treatment: Magnesium sulfate · Normal Saline — In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Lab requirements
Kidney function
eGFR <45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy [excluded]
Cardiac function
Sinus bradycardia (HR <55 bpm on any ECG in preceding 6 months) [excluded]; High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker [excluded]
eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months. High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify